Investigational drug · Phase 3
HMI-115
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Endometriosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "HMI-115"
First trial start
2026
Jan 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HMI-115", any sponsor or status.
Conditions studied
As listed on its trial records.
- Endometriosis
Approved drugs for the same conditions: Endometriosis · Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "HMI-115" as an intervention, largest first.
- Evaluate the Efficacy and Safety of HMI-115 in Women With Moderate to Severe Endometriosis-associated PainPivotal-lookingRecruiting
Hope Medicine (Nanjing) Co., LtdIndustry
NCT07318688 · 540 participants (planned) · Start Jan 29, 2026 · Primary completion Mar 1, 2028
Drug: HMI-115; Placebo · For: Endometriosis
Sites: Beijing, China; Nanning, China; Suzhu, China · 5 sites in all
- A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic AlopeciaPivotal-lookingCompleted
Hope Medicine (Nanjing) Co., LtdIndustry
NCT06118866 · 192 participants · Start Sep 11, 2023 · Primary completion Aug 26, 2024
Drug: placebo-Q2W; HMI-115-120mg-Q4W and 2 more · For: Androgenetic Alopecia
Sites: Beijing, China
- A Study to Assess the Efficacy and Safety of HMI-115 in Subjects With Endometriosis-Associated PainPivotal-lookingCompleted
Hope Medicine (Nanjing) Co., LtdIndustry
NCT05101317 · 142 participants · Start Oct 11, 2021 · Primary completion Sep 26, 2024
Drug: HMI-115; Placebo · For: Endometriosis
Sites: Draper, Utah; Norfolk, Virginia; Beijing, China · 5 sites in all
Hope Medicine (Nanjing) Co., LtdIndustry
NCT05324293 · 16 participants · Start May 11, 2022 · Primary completion Sep 11, 2023
Drug: HMI-115 · For: Androgenetic Alopecia
Sites: Melbourne E., Australia
Newest research
PubMed records naming it or its code names, newest first.
- Emerging pharmacotherapies for androgenetic alopecia.
Agrawal A, Dreifus EM, Tosti A · Expert Opin Pharmacother 2026
- Single-cell RNA sequencing identifies the prolactin receptor as a therapeutic target in adenomyosis.
Wang R, Xu S, Cui Q, et al. · Signal Transduct Target Ther 2025
Also in development for Endometriosis
- Leuprorelin acetateLeuprolide Open Label, DKF-MA102Phase 33 trials
Pfizer · Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
- KLH-2109Phase 32 trials
JW Pharmaceutical · Menorrhagia, Uterine Fibroids, Endometriosis
- OG-6219Phase 21 trial
Organon and Co · Endometriosis
- VipoglanstatPhase 21 trial
Gesynta Pharma AB · Endometriosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.